The rebound weight gain seen after stopping Retatrutide is best explained as the body re-asserting a lipostat (“fat thermostat”) that the drug never actually moved. Across the excerpts two converging lines of evidence make this clear.
First, every pharmacologic or peptide-induced weight loss is followed by a predictable neuro-endocrine counter-attack. Within days of fat loss, ghrelin rises, leptin falls, and the hypothalamus rewires itself to strengthen feeding circuits and weaken satiety circuits. Grossman & Kurzweil summarise the University-of-Washington data showing that ghrelin surges after rapid weight loss and literally “undoes the neural changes from earlier administration of leptin,” while Guyenet notes that the hypothalamus “usually wins in the end” because it commands slower metabolism, greater hunger, and higher food reward. These compensations are not side-effects; they are the body’s evolved defence against what it interprets as famine. Retatrutide, like semaglutide or tirzepatide, simply mutes that defence while the molecule is on board; once the weekly injection is withdrawn the defence returns at full strength, and the prior weight trajectory resumes. The set-point has not been “lowered”; it has been silenced pharmacologically.
Second, the set-point itself is plastic upward but sticky downward. Hari records the dominant obesity-research view that “as you gain weight your set-point rises,” and Guyenet underlines that “the set-point can move upward… but trying to push it back down triggers the starvation response.” The asymmetry is why calorie restriction or any temporary anorectic – peptide or not – almost always fails long-term. Fung is blunt: “you can temporarily force your body weight lower… the resulting lowered metabolism will raise your weight back to normal.” Nothing in the excerpts suggests that Retatrutide has overcome this asymmetry; the drug drives weight loss by co-opting the same glucagon/GLP-1/GIP pathways that blunt appetite and slow gastric emptying, not by re-programming the defended level of adiposity.
The most counter-intuitive finding is that the brain appears to store a “memory of the weight it wants the animals to be” (Grossman & Kurzweil, commenting on the leptin-ghrelin rewiring study). That memory is encoded in synaptic strengths inside the hypothalamus and can be erased only transiently. This implies that any peptide which does not durably rewire those synapses – and no evidence in the corpus shows Retatrutide does – is destined to lose the tug-of-war once treatment stops.
A critical gap is explicitly acknowledged: researchers still do not know how to move the set-point downward in humans without continuous pharmacologic pressure. Leptin replacement cures the handful of people who lack leptin, but as The Healing Self notes, “the story quickly grew more complicated” when ordinary obesity showed leptin resistance, not deficiency. CART-peptide infusions in rodents (Handbook of Biologically Active Peptides) lower weight, but human durability and safety are unstudied. Thus the corpus contains no example of a peptide therapy that achieves a permanent downward reset.
Taken together, the rebound after Retatrutide is not a sign that the drug “damaged” metabolism; rather, the drug never completed the harder task of persuading the lipostat that a lower weight is now “normal.” Until a therapy can durably rewire the hypothalamic circuits that Guyenet calls “the lipostat,” weight will snap back when the pharmacologic brake is released.
References
- Fantastic voyage _ live long enough to live forever — Grossman
- Terry
- Kurzweil
- Kurzweile
- Good calories, bad calories challenging the conventional — Taubes
- Grow young with HGH _ the amazing medically proven plan to
- Handbook of Biologically Active Peptides
- Magic Pill The Extraordinary Benefits and Disturbing Risks — Johann Hari
- The Healing Self _ A Revolutionary New Plan to Supercharge
- The Obesity Code Unlocking the Secrets of Weight Loss (Why — Jason Fung